Dublin, Nov. 26, 2024 (GLOBE NEWSWIRE) — The “Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions” report has been added to ResearchAndMarkets.com’s offering.
The global antibody drug conjugate market is estimated to grow from USD 7.72 billion in the current year to USD 23.3 billion by 2035, at a CAGR of 9.63% during the forecast period, till 2035.
Over the years, various technical developments, such as enhanced pharmacokinetic and pharmacodynamic properties and antibody engineering have paved the way for antibody drug conjugates to be considered as a viable therapeutic modality for the treatment of solid tumors and hematological malignancies. To date, over 280 antibody drug conjugates have been either approved or being investigated in clinical studies, whereas more than 250 candidates are in the early stages of development. Examples of the USFDA approved drugs include Zynlonta, Akalux, Aidixi.
Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side effects. Till date, several clinical trials have shown the therapeutic superiority (over conventional cancer treatment options) and efficacy of antibody-drug conjugates. Therefore, the rising population of various oncological disorders is one of the key drivers for the antibody drug conjugate market. Driven by the availability of innovative technology platforms, lucrative funding opportunities and encouraging clinical trial results, the antibody drug conjugates market is poised to grow in the long-run, as multiple product candidates are expected to receive marketing approval in the coming decade.
Antibody Drug Conjugate Market: Key Insights
The report delves into the current state of the antibody drug conjugate market and identifies potential growth opportunities within the industry.
Some key findings from the report include:
- The landscape of ADCs has steadily evolved over the past decade; more than 530 ADC therapy programs are being evaluated by over 140 drug developers, worldwide.
- Currently, 47% of the ADCs are in discovery / preclinical stages of development; of these, close to 160 ADCs utilize auristatin and maytansinoid payloads.
- In order to gain a competitive edge, ADC developers are actively exploring novel targets for the treatment of a wide array of indications.
- Since 2010, 560+ clinical trials have been registered to evaluate the safety and efficacy of various ADCs; majority of these studies have been conducted across various sites in the US.
- Developers have already evaluated more than 190 ADCs in combination with other therapeutic modalities for the treatment of various oncological disorders.
- The growing interest in this field is evident from the rise in partnership activity over the years; in fact, the maximum partnerships, till date, were inked recently.
- Considering the enormous opportunities associated with ADCs for the treatment of cancer, investors have readily extended funds, worth nearly USD 30 billion, in the last decade.
- Several researchers from renowned universities, currently involved in evaluating efficacy and safety of ADCs, have emerged as prominent KOLs.
- Over the years, the intellectual capital related to the therapeutic applications of ADCs has grown at a commendable pace; more than 3,330 patents have been filed by both industry and non-industry players.
- A number of grants, worth over USD 135 million, have been awarded for research activity related to ADCs; nearly 90% of these grants extend a support period of up to 10 years.
- Stakeholders are exploring diverse commercialization strategies across different stages of a drug’s launch cycle; for drugs nearing patent expiry, these developers are expected to adopt lifecycle management strategies.
- Presently, around 35 players, across the globe, claim to have the required capabilities to offer contract manufacturing / conjugation services for ADCs; of these, over 10 players claim to be one-stop-shops.
- With a promising developmental pipeline, the global market is anticipated to witness an annualized growth of nearly 10% over the next decade.
ANTIBODY DRUG CONJUGATE MARKET: KEY SEGMENTS
Breast Cancer is Likely to Dominate the Antibody Drug Conjugate Market During the Forecast Period
Based on the target disease indication, the market is segmented into breast cancer, b-cell lymphoma, lung cancer, multiple myeloma, acute lymphoblastic leukemia, gastric cancer, renalcancer, cervical cancer and other target disease indications. Currently, a number of antibody drug conjugates have been approved for the treatment of breast cancer patients. This segment is expected to capture the largest share as more drug candidates receive approvals in the future.
Currently, Solid Tumor Holds Maximum Share within the Antibody Drug Conjugate Market
Based on the therapeutic area, the market is segmented into hematological cancer and solid tumor. It is worth highlighting that antibody drug conjugate market for solid tumor is likely to grow at a relatively higher CAGR, during the forecast period.
Maleimidocaproyl is the Fastest Growing Segment in the Antibody Conjugate Market During the Forecast Period
Based on the type of linker, the market is segmented into valine-citrulline, succinimidyl-4-(n-maleimidomethyl) cyclohexane-1-carboxylate, tetrapeptide-based linker, maleimidocaproyl, valine-alanine, hydrazone (4-(4-acetylphenoxy) butanoic acid (acbut) and other linkers. It is worth highlighting that the current antibody drug conjugate market is dominated by valine-citrulline linkers.
Monomethyl auristatin E (MMAE) Payload is Likely to Dominate the Antibody Drug Conjugate Market During the Forecast Period
Based on the type of payload, the market is segmented into Monomethyl Auristatin E, DM1, Duocarmycin, SN-38 / Irinotecan, Monomethyl Auristatin F, SG3199, Ozogamicin, DM4 and other Payloads. The current market is expected to be driven by MMAE payload used in antibody drug conjugates, followed by DM1; a similar trend is anticipated in the long term.
Currently, HER-2 (ERBB2) Target Antigen Holds the Maximum Share within the Antibody Drug Conjugate Market
Based on the target antigen, the market is segmented into HER-2 (ERBB2), CD79b, Trop-2, BCMA (TNFRSF17 / BCM), CD19, CD22, tissue factor, CD30, CEACAM5, Nectin 4 and others.
The market is expected to be driven by HER-2 (ERBB2) antigen, CD79b target antigen and TROP-2 antigen in mid-long term. It is worth highlighting that the antibody drug conjugate market for tissue factor is likely to grow at a relatively higher CAGR during the forecast period.
North America Accounts for the Largest Share of the Market
Based on key geographical regions, the market is segmented into North America, Europe and Asia-Pacific. Majority share is expected to be captured by drug developers based in North America and Europe. It is worth highlighting that over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.
Key Players in the Antibody Drug Conjugates Market
- ADC Therapeutics
- Astellas Pharma
- AstraZeneca
- Byondis
- Daiichi Sankyo
- Genentech
- Gilead Sciences
- ImmunoGen
- Pfizer
- RemeGen
Key Questions Answered in this Report
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What kind of partnership models are commonly adopted by industry stakeholders?
- What are the factors that are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Additional Benefits
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 10% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
- Free Updated report if the report is 6-12 months old or older
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Antibody Drug Conjugates: Therapies Pipeline
4.3. Antibody Drug Conjugate: List of Therapy Developers
5. TARGET COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Parameters
5.3. Methodology
5.4. Target Competitiveness Analysis: Key Targets of Antibody Drug Conjugates
6. COMPANY AND DRUG PROFILES
- ADC Therapeutics
- Astellas Pharma
- AstraZeneca
- Byondis
- Daiichi Sankyo
- Genentech (Subsidiary of Roche)
- Gilead Sciences
- ImmunoGen
- Pfizer
- RemeGen
- Seagen
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Antibody Drug Conjugates: Clinical Trial Analysis
8. KEY OPINION LEADERS
8.1. Chapter Overview
8.2. Assumption and Key Parameters
8.3. Methodology
8.4. Antibody Drug Conjugates: Key Opinion Leaders
9. COMBINATION THERAPIES
9.1. Chapter Overview
9.2. Combination Therapies: History of Development
9.3. Combination Therapies: FDA Guidelines
9.4. Combination Therapies: Antibody Drug Conjugates
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Antibody Drug Conjugates: List of Partnerships and Collaborations
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Antibody Drug Conjugates: List of Funding and Investment Analysis
12. PATENT ANALYSIS
12.1.Chapter Overview
12.2. Scope and Methodology
12.3. Antibody Drug Conjugates: Patent Analysis
13. ACADEMIC GRANTS ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Antibody Drug Conjugates: Grants Analysis
14. KEY COMMMERCIALIZATION STRATEGIES
14.1. Chapter Overview
14.2. Successful Drug Launch Strategy: ROOTS Framework
14.3. Successful Drug Launch Strategy: Product Differentiation
14.4. Common Commercialization Strategies Adopted Across Different Stages of Product Development
14.5. Key Commercialization Strategies Adopted by the Companies Focused on Antibody Drug Conjugates
15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website
15.4. Summary of Patient Support Services and Informative Downloads
- Adcetris
- Besponsa
- Enhertu
- Kadcyla
- Mylotarg
- Polivy
- Trodelvy
16. SUCCESS PROTOCOL ANALYSIS
16.1. Chapter Overview
16.2. Antibody Drug Conjugates: Success Protocol Analysis
- Adcetris (Seagen / Takeda Oncology)
- Aidixi (RemeGen)
- Akalux (Rakuten Medical)
- Besponsa (Pfizer / UCB)
- Blenrep (GlaxoSmithKline)
- Elahere (ImmunoGen)
- Enhertu (Daiichi Sankyo / AstraZeneca)
- Kadcyla (Genentech / ImmunoGen)
- Padcev (Seagen / Astellas Pharma)
- Polivy (Genentech)
- Tivdak (Seagen / Genmab)
- Trodelvy (Gilead Sciences)
- Zynlonta (ADC Therapeutics)
17. NOVEL CONJUGATION AND LINKER TECHNOLOGY PLATFORMS
17.1. Chapter Overview
17.2. Antibody Drug Conjugates: Conjugation Technologies
17.3. Antibody Drug Conjugates: List of Conjugation Technologies
17.4. Antibody Drug Conjugates: Linker Technologies
17.5. Antibody Drug Conjugates: List of Linker and Linker-Payload Technologies
18. ASSESSMENT OF NON-CLINICAL DATA FIRST IN HUMAN DOSING
18.1. Chapter Overview
18.2. Antibody Drug Conjugates: Non-Clinical Studies
18.3. ICH S9 Guidelines
18.4. Investigational New Drug (IND)-Enabling Study Designs
18.5. Toxicities in Animal Models
18.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
19. COST PRICE ANALYSIS
19.1. Chapter Overview
19.2. Factors Contributing Towards the High Price of Antibody-Drug Conjugates
19.3. Antibody Drug Conjugates Market: Cost Price Analysis
19.4. Reimbursement Considerations for Antibody-Drug Conjugates
20. CASE STUDY 1: CONTRACT MANUFACTURING OF ANTIBODY-DRUG CONJUGATES
20.1. Chapter Overview
20.2. Key Steps in Antibody Drug Conjugate Manufacturing Process
20.3. Technical Challenges Related to Antibody Drug Conjugate Manufacturing
20.4. Challenges Associated with Supply Chain and Method Transfer
20.5. Limitations of In-House Manufacturing
20.6. Investments in Antibody Drug Conjugate Manufacturing Capability Expansions
20.7. Collaborations Established for Antibody-Drug Conjugate Manufacturing
20.8. Growing Demand for Antibody-Drug Conjugate Contract Manufacturing
20.9. CMOs with Linker Manufacturing Capabilities
20.10. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
20.11. CMOs with Conjugation Capabilities
20.12. Antibody Drug Conjugate One-Stop-Shops
20.13. Increasing Demand for One-Stop-Shops
21. CASE STUDY 2: COMPANION DIAGNOSTICS FOR ANTIBODY DRUG CONJUGATES THERAPEUTICS
21.1. Chapter Overview
21.2. Companion Diagnostics for Antibody Drug Conjugates
21.3. Companion Diagnostics For Antibody Therapeutics
22. SWOT ANALYSIS
23. MARKET FORECAST AND OPPORTUNITY ANALYSIS
23.1. Chapter Overview
23.2. Forecast Methodology and Key Assumptions
23.3. Global Antibody Drug Conjugates Market, till 2035
23.4. Antibody Drug Conjugates Market: Product-wise Sales Forecast to 2035
- Adcetris
- Aidixi
- Besponsa
- Blenrep
- Elahere
- Enhertu
- Kadcyla
- Padcev
- Polivy
- Tivdak
- Trodelvy
- Zynlonta
- Datopotamab Deruxtecan
- Patritumab Deruxtecan
- SHR-A1811
- SKB264
- TAA013
- Telisotuzumab Vedotin
- Trastuzumab Duocarmazine
- Tusamitamab Ravtansine
- Upifitamab Rilsodotin
For more information about this report visit https://www.researchandmarkets.com/r/keqmqc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- ADC Development Pipeline
- ADC Combination Therapies
